MedTrace Logo

A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease

NCT00607308 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-12-07

No results posted yet for this study

Summary

The purpose of this study is to examine the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single dose of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's Disease.

Conditions

Interventions

BIOLOGICAL

PF-04360365

Single dose of 0.1 mg/kg IV on Day 1

BIOLOGICAL

PF-04360365

Single dose of 0.5 mg/kg IV on Day 1

BIOLOGICAL

PF-04360365

Single dose of 1 mg/kg IV on Day 1

BIOLOGICAL

PF-04360365

Single dose of 5 mg/kg IV on Day 1

DRUG

Placebo

Single dose of placebo IV on Day 1

BIOLOGICAL

PF-04360365

Single dose of 10 mg/kg IV on Day 1

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00607308 on ClinicalTrials.gov